Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.
Ost P, Siva S, Brabrand S, Dirix P, Liefhooghe N, Otte FX, Gomez-Iturriaga A, Everaerts W, Shelan M, Conde-Moreno A, López Campos F, Papachristofilou A, Guckenberger M, Scorsetti M, Zapatero A, Villafranca Iturre AE, Eito C, Couñago F, Muto P, Van De Voorde L, Mach N, Bultijnck R, Fonteyne V, Moon D, Thon K, Mercier C, Achard V, Stellamans K, Goetghebeur E, Reynders D, Zilli T. Ost P, et al. Among authors: stellamans k. Eur Urol Oncol. 2024 Jun;7(3):462-468. doi: 10.1016/j.euo.2023.09.007. Epub 2023 Oct 9. Eur Urol Oncol. 2024. PMID: 37821242 Clinical Trial.
Subjective, but not objective, cognitive complaints impact long-term quality of life in cancer patients.
Lycke M, Lefebvre T, Pottel L, Pottel H, Ketelaars L, Stellamans K, Van Eygen K, Vergauwe P, Werbrouck P, Cool L, Boterberg T, Liefhooghe N, Schofield P, Debruyne PR. Lycke M, et al. Among authors: stellamans k. J Psychosoc Oncol. 2019 Jul-Aug;37(4):427-440. doi: 10.1080/07347332.2018.1504154. Epub 2019 Feb 23. J Psychosoc Oncol. 2019. PMID: 30798774 Clinical Trial.
The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases.
Zilli T, Dirix P, Heikkilä R, Liefhooghe N, Siva S, Gomez-Iturriaga A, Everaerts W, Otte F, Shelan M, Mercier C, Achard V, Thon K, Stellamans K, Moon D, Conde-Moreno A, Papachristofilou A, Scorsetti M, Gückenberger M, Ameye F, Zapatero A, Van De Voorde L, López Campos F, Couñago F, Jaccard M, Spiessens A, Semac I, Vanhoutte F, Goetghebeur E, Reynders D, Ost P. Zilli T, et al. Among authors: stellamans k. Eur Urol Focus. 2021 Mar;7(2):241-244. doi: 10.1016/j.euf.2020.12.010. Epub 2020 Dec 29. Eur Urol Focus. 2021. PMID: 33386290 Free article. Clinical Trial.
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium.
Kroeze SGC, Pavic M, Stellamans K, Lievens Y, Becherini C, Scorsetti M, Alongi F, Ricardi U, Jereczek-Fossa BA, Westhoff P, But-Hadzic J, Widder J, Geets X, Bral S, Lambrecht M, Billiet C, Sirak I, Ramella S, Giovanni Battista I, Benavente S, Zapatero A, Romero F, Zilli T, Khanfir K, Hemmatazad H, de Bari B, Klass DN, Adnan S, Peulen H, Salinas Ramos J, Strijbos M, Popat S, Ost P, Guckenberger M. Kroeze SGC, et al. Among authors: stellamans k. Lancet Oncol. 2023 Mar;24(3):e121-e132. doi: 10.1016/S1470-2045(22)00752-5. Lancet Oncol. 2023. PMID: 36858728 Review.
Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: Real-world data from the E2-RADIatE OligoCare cohort.
Bultijnck R, Van Hemelrijck M, Fonteyne V, Livi L, Jereczek-Fossa BA, Hemmatazad H, Mayinger M, Peulen H, Verbeke L, Ramella S, Castro P, Tsoutsou P, Stellamans K, Shaukat A, Orazem M, Jeene P, Braam P, Verkooijen H, Simek IM, Alongi F, Clementel E, Fortpied C, Machingura A, Boakye Oppong F, Guckenberger M, Ost P. Bultijnck R, et al. Among authors: stellamans k. Clin Transl Radiat Oncol. 2023 Dec 29;45:100715. doi: 10.1016/j.ctro.2023.100715. eCollection 2024 Mar. Clin Transl Radiat Oncol. 2023. PMID: 38274388 Free PMC article.
Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.
King MT, Link EK, Whelan TJ, Olivotto IA, Kunkler I, Westenberg AH, Gruber G, Schofield P, Chua BH; BIG 3-07/TROG 07.01 trial investigators. King MT, et al. Lancet Oncol. 2020 May;21(5):685-698. doi: 10.1016/S1470-2045(20)30085-1. Epub 2020 Mar 20. Lancet Oncol. 2020. PMID: 32203696 Clinical Trial.
Underrepresentation of vulnerable older patients with cancer in phase II and III oncology registration trials: A case-control study.
Tack L, Lefebvre T, Lycke M, Pottel L, Cool L, Ketelaars L, De Zutter J, Martens E, Pottel H, Stellamans K, Van Eygen K, Werbrouck P, Vergauwe P, Wildiers H, Schofield P, Boterberg T, Debruyne PR. Tack L, et al. Among authors: stellamans k. J Geriatr Oncol. 2020 Mar;11(2):320-326. doi: 10.1016/j.jgo.2019.09.003. Epub 2019 Oct 14. J Geriatr Oncol. 2020. PMID: 31619371 Clinical Trial.
Radiotherapy-specific quality indicators at national level: How to make it happen.
Vaandering A, Jansen N, Weltens C, Moretti L, Stellamans K, Vanhoutte F, Scalliet P, Remouchamps V, Lievens Y; Belgian College for Physicians in Radiation Oncology. Vaandering A, et al. Among authors: stellamans k. Radiother Oncol. 2023 Jan;178:109433. doi: 10.1016/j.radonc.2022.11.022. Epub 2022 Dec 1. Radiother Oncol. 2023. PMID: 36464181 Free article.
The distress thermometer predicts subjective, but not objective, cognitive complaints six months after treatment initiation in cancer patients.
Lycke M, Lefebvre T, Pottel L, Pottel H, Ketelaars L, Stellamans K, Eygen KV, Vergauwe P, Werbrouck P, Goethals L, Schofield P, Boterberg T, Debruyne PR. Lycke M, et al. Among authors: stellamans k. J Psychosoc Oncol. 2017 Nov-Dec;35(6):741-757. doi: 10.1080/07347332.2017.1365798. Epub 2017 Aug 17. J Psychosoc Oncol. 2017. PMID: 28816636 Clinical Trial.
23 results